Search
Now showing items 1-2 of 2
Targeted treatment in patients with non-small cell lung cancer: Use of Bevacizumab and its Biosimilars
(Brac University, 2021-04)
Angiogenesis is one of the pivotal factors contributing to the development and metastasis of non small cell lung cancer which is one of the most commonly diagnosed types of lung cancer.
Bevacizumab, a monoclonal antibody ...
Concepts and challenges of biosimilars to mitigate the oncology drug expenses
(Brac University, 2021-02)
Biosimilars is way more likely to genuine generic drugs of the innovator. Time to time expiry
of generic drugs helps manufacturer to think about biosimilars which has wide cost
effectiveness as well as expanded patient ...